Q-omics provides the consensus-scored ANKRD13D profile across patient tissues and cancer cell-line models. ANKRD13D expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD13D is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ANKRD13D RNA expression shows 18,537 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where ANKRD13D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD13D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD13D survival associations across molecular data types. ANKRD13D RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD13D RNA expression–survival associations across cancer types. High ANKRD13D expression shows unfavorable associations in KIRC, ACC, UVM, COAD, LIHC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD13D RNA expression.
This table summarizes ANKRD13D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD13D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD13D shows higher tumor expression in COAD, KIRC, HNSC, LIHC, THCA and BLCA. The COAD box plot shows higher ANKRD13D RNA expression in tumor versus normal tissue (log2 FC = +1.382, t-test p < 0.001).
This table shows molecular features associated with ANKRD13D in patient tissues and cancer cell lines. In patient samples, ANKRD13D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD13D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
